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and the common consequences were fractures and head injuries.
The common bones fractured were the radius and ulna.
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OBJECTIVES: The objective of this study was to assess the
impact of a PDA-e-prescribing tool (e-tool) on prescribing poten-
tially inappropriate drugs from the Beers List to the elderly. The
Beers List documents potentially inappropriate medications that
should be avoided or used with caution in patients over the age
of 65 years. METHODS: All prescription claims (N = 383,855)
from April 2002 through June 2005 were extracted for 14,557
plan participants aged 65 and older in which 70 of 3706 pre-
scribers received an e-tool. For each claim, we identiﬁed whether
the prescription was new and a Beers listed drug and whether
the prescriber was an e-tool user and a staff model physician. E-
tool use was split into before and after initiation. New prescrip-
tions were classiﬁed into 6 and 12-month variables using prior
eligibility. Rates were determined as Beers claims counts divided
by total claims. We ran chi-square tests and logistic regressions
incorporating these and selected demographic variables.
RESULTS: After initiating e-tool use, providers prescribed sig-
niﬁcantly fewer Beers drugs than before across all (7.87% vs.
9.13%, p < 0.0001) and new (6-month: 3.39% vs. 4.68%, p <
0.0056; 12-month: 3.05% vs. 4.78%, p < 0.0025) prescriptions;
their before rates did not differ signiﬁcantly from non-e-tool
providers (overall: 9.09% vs. 9.13%, p = 0.8702; 6-month:
5.04% vs. 4.66%, p = 0.5459; 12-month: 3.05% vs. 4.78%, 
p < 0.9317). Staff providers prescribed signiﬁcantly fewer Beers
drugs overall than non-staff providers (8.88% vs. 9.27%, p =
0.0002), but not for 6-month (5.08% vs. 4.49%, p = 0.0558) or
12-month (4.97% vs. 4.69%, p = 0.5816) new prescriptions.
Regressions, accounting for provider degree and specialty, par-
ticipant sex and age group, and geography, yielded similar
results. CONCLUSION: e-Tools providing Beers criteria can sig-
niﬁcantly reduce the prescribing of these drugs among the elderly.
Such reductions have been shown to reduce morbidity, mortal-
ity, and health care costs.
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OBJECTIVES: The objective of this study was to identify the
most cost-effective oral or transdermal contraceptives (CCs)
using a provider perspective. METHODS: A decision analytic
model was developed to compare the cost-effectiveness of oral
CCs, 3 mg drospirenone/0.02 mg Ethinylestradiaol (DRSP-EE),
0.18 mg norgestimate/0.025 mg ethinylestradiol (NO-EE), and 
1 mg norethindrone acetate/20 mcg ethinyl estradiol (NA-EE);
transdermal CC 6 mg norelgestromin/0.075 mg ethinyestradiol
(transdermal N-EE); and no contraceptive use in preventing a
pregnancy per patient per year. Direct medical costs were based
on average wholesale prices for drugs (Wolters-Kluwer, 2006),
and, physician, laboratory and hospital costs based on 2006
Medicare reimbursement rates. Probability data that included
compliance and pregnancy rates were extracted from random-
ized clinical trials and public resources such as the 2002 National
Survey of Family Growth. A probabilistic sensitivity analysis of
all free parameters was conducted through a Monte Carlo sim-
ulation. Key parameters were sampled from beta distributions.
RESULTS: In the base case, DRSP-EE was found to be the most
cost-effective strategy. DRSP-EE cost $688 compared to $766 for
NA-EE, $736 for transdermal N-EE, and $729 for NO-EE to
prevent a single pregnancy per patient per year. No contracep-
tive use was the least cost-effective strategy, resulting in approx-
imately $52,529 to prevent a single pregnancy per patient per
year. Monte Carlo sensitivity analysis conﬁrmed these ﬁndings.
Incremental cost-effectiveness analyses revealed that the use of
transdermal N-EE costs an additional $86,285 per patient per
year to be as effective as DRSP-EE. CONCLUSION: In terms of
cost-effectiveness, DRSP-EE dominated all contraceptive strate-
gies. The overarching component driving differences in cost-
effectiveness was related to direct medical costs associated with
pregnancy. These direct medical costs, in turn, were driven by
differential compliance and efﬁcacy rates that favored DRSP-EE.
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OBJECTIVES: Estimate annual direct (medical expenditure) and
indirect (absenteeism and short-term disability) costs for women
with uterine ﬁbroids (UF). METHODS: We compared 12-month
direct costs among women aged 18–54 with clinically-signiﬁcant,
symptomatic UF (admission, emergency visit, or >2 ofﬁce visits
>30 days apart with a UF diagnosis) to a 1 : 1 propensity score
matched cohort of women without UF, using the MarketScan
Commercial Claims and Encounters insurance database data
from for 2000–2004. We also compared indirect costs for the
sub-sample of women with available data. Exponential condi-
tional regression analysis controlled for confounding factors, and
costs were adjusted to 2004 levels. RESULTS: Sample sizes for
the direct and indirect costs analyses were 38,020 and 1820,
respectively. Mean 12-month direct costs for women in the UF
group were $11,720 vs. $3257 for controls (women without
diagnosed or treated ﬁbroids). Mean 12-month indirect costs
were $11,752 and $8083 for women in the UF group and con-
trols, respectively. Estimated direct costs attributable to UF were
therefore $8463 (p < 0.001) and indirect costs were $3669 (p <
0.001). Employers’ share of direct costs ranged from 84.1% to
87.5%. CONCLUSION: Direct and indirect costs of uterine
ﬁbroids represent a substantial burden to employers. Treatment
options aimed at reducing symptoms and resultant absenteeism
are needed to improve women’s health and productivity.
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OBJECTIVES: To estimate the direct cost of surgical interven-
tions for Pelvic Organ Prolapse (POP) to the payers in Germany,
France and the National Health Service (NHS) in England.
